Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Overview: The demand for programming skills in 2026 centres around versatility, performance, and scalability as companies ramp up AI, cloud, and web services.La ...

As the global population ages, 2025 has delivered a remarkable wave of new research aimed at supporting healthier brains in ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, ...

The daily burden for those living with type 1 diabetes is constant, and Breakthrough T1D remains focused on accelerating the path to cures for the disease,” said Nicholas Mamrak, Ph.D., scientist at ...

A new study led by scientists at the Perception Dynamics Institute and the University of California San Diego demonstrates ...

Another driver arrested in one of last week’s RIDE programs was charged with impaired driving at a holiday season spot check ...